Keskin Guler Selda, Aytac Bilal, Durak Zahide Esra, Gokce Cokal Burcu, Gunes Nalan, Durak Ilker, Yoldas Tahir
Department of Adult Neurology, Ankara Training and Research Hospital, Şükriye District, Ulucanlar Avenue, No: 89, Altındağ, 06340, Ankara, Turkey.
General Directorate of Health Information Systems, Ministry of Health, Ankara, Turkey.
Neurol Sci. 2016 May;37(5):763-7. doi: 10.1007/s10072-016-2494-0. Epub 2016 Feb 1.
Oxidative stress has been implicated in various disorders, including epilepsy. The aim of this study was to investigate the oxidant and antioxidant status of patients with epilepsy using antiepileptic drugs regularly and to compare them with healthy subjects. We investigated serum catalase (CAT), malondialdehyde (MDA), glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), and xanthine oxidase (XO) levels in 58 epilepsy patients and 25 healthy controls. Patients were divided into polytherapy (n = 17) and monotherapy (n = 41) groups, and antioxidant status was compared between the two groups and controls. There was no significant difference between the patient and control groups in terms of age or gender (p > 0.05). The mean duration of illness in the patients was 14.8 years, and the mean duration of treatment was 11.4 years. Comparison of the patient and control groups in terms of oxidative stress and antioxidant defence parameters revealed significantly higher MDA, GSH-Px, XO and lower level of CAT, SOD levels (p < 0.05). There were no differences in CAT, MDA, GSH-Px or SOD levels between the monotherapy and polytherapy groups; but the XO level was higher in the monotherapy group (p < 0.05). Although the XO level was decreased by polytherapy, it was higher than in controls. Our study found significantly low level of antioxidants in patients with epilepsy as compared to control. Thus, antiepileptic treatment did not improve oxidative stress parameters. Furthermore, our results show that polytherapy does not change the situation as compared with monotherapy. Antioxidant replacement therapy may benefit these patients.
氧化应激与包括癫痫在内的多种疾病有关。本研究的目的是调查定期使用抗癫痫药物的癫痫患者的氧化剂和抗氧化剂状态，并将其与健康受试者进行比较。我们调查了58例癫痫患者和25例健康对照者的血清过氧化氢酶（CAT）、丙二醛（MDA）、谷胱甘肽过氧化物酶（GSH-Px）、超氧化物歧化酶（SOD）和黄嘌呤氧化酶（XO）水平。患者分为联合治疗组（n = 17）和单药治疗组（n = 41），并比较两组与对照组的抗氧化状态。患者组和对照组在年龄或性别方面无显著差异（p>0.05）。患者的平均病程为14.8年，平均治疗时间为11.4年。对患者组和对照组的氧化应激和抗氧化防御参数进行比较，结果显示MDA、GSH-Px、XO显著升高，而CAT、SOD水平降低（p<0.05）。单药治疗组和联合治疗组之间的CAT、MDA、GSH-Px或SOD水平无差异；但单药治疗组的XO水平较高（p<0.05）。虽然联合治疗可降低XO水平，但仍高于对照组。我们的研究发现，与对照组相比，癫痫患者的抗氧化剂水平显著降低。因此，抗癫痫治疗并未改善氧化应激参数。此外，我们的结果表明，与单药治疗相比，联合治疗并未改变这种情况。抗氧化剂替代疗法可能对这些患者有益。
